The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease.

The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Hydrogenation catalysts for aromatic hydrogenation including an organosilica material support, which is a polymer comprising independent units of a monomer of Formula [Z.sup.1OZ.sup.2OSiCH.sub.2].sub.3 (I), wherein each Z.sup.1 and Z.sup.2 independently represent a hydrogen atom, a C.sub.1-C.sub.4 alkyl group or a bond to a silicon atom of another monomer; and at least one catalyst metal are provided herein. Methods of making the hydrogenation catalysts and processes of using, e.g., aromatic hydrogenation, the hydrogenation catalyst are also provided herein.

Hydrogenation catalysts for aromatic hydrogenation including an organosilica material support, which is a polymer comprising independent units of a monomer of Formula [Z.sup.1OZ.sup.2OSiCH.sub.2].sub.3 (I), wherein each Z.sup.1 and Z.sup.2 independently represent a hydrogen atom, a C.sub.1-C.sub.4 alkyl group or a bond to a silicon atom of another monomer; and at least one catalyst metal are provided herein. Methods of making the hydrogenation catalysts and processes of using, e.g., aromatic hydrogenation, the hydrogenation catalyst are also provided herein.

A porous aluminum-based metal-organic framework (MOF) comprises inorganic aluminum chains linked via carboxylate groups of 1H-pyrazole-3,5-dicarboxylate (HPDC) linkers, and of formula: [Al(OH)(C.sub.5H.sub.2O.sub.4N.sub.2)(H.sub.2O)].

The present invention relates to a hybrid membrane mixed with nanoparticles including a zeolitic imidazolate framework (ZIF), and a gas separation method using the same. A hybrid membrane according to the present invention comprises a polymer matrix, and nanoparticles which are dispersed in the polymer matrix and include the ZIF.

A new crystalline aluminosilicate zeolite comprising a novel framework has been synthesized that has been designated UZM-55. This zeolite is represented by a three-dimensional framework of at least SiO.sub.2 tetrahedral units and an empirical composition in the as-synthesized and anhydrous basis expressed by an empirical formula of:
M.sub.m.sup.n+R.sub.rAl.sub.xE.sub.ySiO.sub.z
where M represents a metal or metals from zinc or Group 1 (IUPAC 1), Group 2 (IUPAC 2), Group 3 (IUPAC 3) or the lanthanide series of the periodic table, R is a structure directing agent or agents such as 1,6-bis(N-methylpiperidinium)hexane, and E is an element selected from the group consisting of gallium, iron, boron and mixtures thereof. Catalysts made from UZM-55 have utility in various hydrocarbon conversion reactions including methanol to hydrocarbons (MTH).

A new crystalline aluminosilicate zeolite comprising a novel framework has been synthesized that has been designated UZM-55. This zeolite is represented by a three-dimensional framework of at least SiO.sub.2 tetrahedral units and an empirical composition in the as-synthesized and anhydrous basis expressed by an empirical formula of:
M.sub.m.sup.n+R.sub.rAl.sub.xE.sub.ySiO.sub.z
where M represents a metal or metals from zinc or Group 1 (IUPAC 1), Group 2 (IUPAC 2), Group 3 (IUPAC 3) or the lanthanide series of the periodic table, R is a structure directing agent or agents such as 1,6-bis(N-methylpiperidinium)hexane, and E is an element selected from the group consisting of gallium, iron, boron and mixtures thereof. Catalysts made from UZM-55 have utility in various hydrocarbon conversion reactions including methanol to hydrocarbons (MTH).